Summary box
1) What is already known on this subject? It has been shown that uncontrolled inflammation and cytokine storm can cause death from SARS-Cov-2. Blocking the release of cytokines and reducing inflammation in stages two and three of the infection can be curative for the patient.
2) What are the new findings? Colchicine blocks the upstream inflammatory cascade compared to IL6 and IL1 inhibitors such as tocilizumab / sarilumab and anakinra / canakinumab. It could also be considered as monotherapy or in combination with these drugs. 3) How could it have an impact on clinical practice in the near future? Using anti inflammatory and immunomodulatory drugs in the right doses and timing, avoiding drug interactions can control the delicate inflammatory/immune balance of the SARS-Cov-2 patient.
Keywords : colchicine, sars-cov-2, cytokine, interleukin, coronavirus, pneumonia